Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,508.64 +1,673.33 (+2.71%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Nexstim Plc (NXTMH.HE)
| Previous close | 2.6000 |
| Open | 2.6000 |
| Bid | 2.5300 x N/A |
| Ask | 2.6400 x N/A |
| Day's range | 2.5800 - 2.6900 |
| 52-week range | 2.0300 - 3.8700 |
| Volume | |
| Avg. volume | 10,389 |
| Market cap | 17.793M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings date | 27 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireNexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has signed a non-exclusive strategic alliance agreement with Inomed Inc. for the purpose of strengthening the collaboration of Marketing, Sales, and Application Support between both companies in the United States. Both Nexstim and Inomed will attend the American Association of Neurologic
- GlobeNewswire
Neurosurgery Customer from Germany Orders Nexstim NBS System 5
Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do no
- GlobeNewswire
Nexstim Plc Business Update Q1 2024
Press release, Helsinki, 26 April 2024 at 9 AM (EEST) Nexstim Plc Business Update Q1 2024 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business operations during Q1 2024. CEO Mikko Karvinen’s Business Update In line with our main strategic objective, we have continued to focus on profitable net sales growth. The sales of new systems at the beginning of this year has been slow, which is typical considering that hospitals' budgets focus on purchase
